The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Adenosine A 2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)
Abstract
Objective: Based on new understanding of nondopaminergic pathways involved in Parkinson's disease (PD) pathophysiology, a selective adenosine A 2A receptor antagonist, istradefylline, shows promise for the treatment of PD. Methods: Istradefylline (40mg/day) was studied in levodopa‐treated PD subjects experiencing prominent wearing‐off motor fluctuations. At 23 North American sites, 196 subjects were randomized in a double‐blind, 12‐week outpatient clinical trial of istradefylline (114 completing the trial) or placebo (58 completing the trial). The primary efficacy measure was change from baseline to end point in the percentage of daily awake “off” time, recorded by subjects using a patient PD diary. Secondary end points evaluated “on” time (including “on time with dyskinesia”), the Unified Parkinson's Disease Rating Scale, and a Clinical Global Impression–Improvement of Illness score. Clinical laboratory, electrocardiograms, vital signs, and adverse event monitoring comprised the safety monitoring. Results: After randomization, approximately 88% of subjects completed the double‐blind period. Compared with baseline, the decrease of daily awake “off” time for istradefylline was a mean (± standard deviation) of −10.8 ± 16.6% (95% confidence interval, −13.46 to −7.52) and for placebo, −4.0 ± 15.7% (95% confidence interval, −7.73–0.31; p = 0.007 using two‐way analysis of variance). This effect corresponded to changes from baseline in total daily awake “off” time of −1.8 ± 2.8 hours for istradefylline and −0.6 ± 2.7 hours for placebo ( p = 0.005). Treatment‐emergent adverse effects with istradefylline were generally mild. Interpretation: Istradefylline was safe, well tolerated, and offered a clinically meaningful reduction in “off” time without increased troublesome dyskinesia. Ann Neurol 2008
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Pharmacotherapy: A Pathophysiologic Approach
(1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-5-447_3 · Cited by 2,407
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Recent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,920
Hughes, A. J., Ben-Shlomo, Y., Daniel, S. E., & Lees, A. J. (1992) · Neurology · doi:10.1212/wnl.42.6.1142 · Cited by 1,313
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561 · cited 1×
“Two years after starting L-dopa therapy, however, many patients start to experience fluctuations that interrupt control of parkinsonism, sometimes for up to several hours per day.(3,4) Adjusting the effects of L-dopa (by dosing changes or extenders such as catechol-Omethyltransferase or monoamine oxidase B inhibitors)…”
BackgroundPahwa, R., Factor, S. A., Lyons, K. E., Ondo, W. G., Gronseth, G., Bronte-Stewart, H., Hallett, M., Miyasaki, J., Stevens, J., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000215250.82576.87 · Cited by 499
Diagnosis and Initial Management of Parkinson's Disease
Nutt, J. G., & Wooten, G. F. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp043908 · Cited by 338
Adenosine A 2A receptor antagonist treatment of Parkinson’s disease
Bara-Jimenez, W., Sherzai, A., Dimitrova, T., Favit, A., Bibbiani, F., Gillespie, M., Morris, M. J., Mouradian, M. M., & Chase, T. N. (2003) · Neurology · doi:10.1212/01.wnl.0000073136.00548.d4 · Cited by 327
Randomized trial of the adenosine A 2A receptor antagonist istradefylline in advanced PD
Hauser, R. A., Hubble, J. P., Truong, D. D., & the Istradefylline US-001 Study Group (2003) · Neurology · doi:10.1212/01.wnl.0000081227.84197.0b · Cited by 300
Hauser, R. A., Friedlander, J., Zesiewicz, T. A., Adler, C. H., Seeberger, L. C., O'Brien, C. F., Molho, E. S., & Factor, S. A. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200003000-00003 · Cited by 300
Shoulson, I., Oakes, D., Fahn, S., Lang, A., Langston, J. W., LeWitt, P., Olanow, C. W., Penney, J. B., Tanner, C., Kieburtz, K., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10191 · Cited by 258
Self-citationKanda, T., Jackson, M. J., Smith, L. A., Pearce, R. K. B., Nakamura, J., Kase, H., Kuwana, Y., & Jenner, P. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7350 · Cited by 248
Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease
Ikeda, K., Kurokawa, M., Aoyama, S., & Kuwana, Y. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00694.x · Cited by 224
Aoyama, S., Kase, H., & Borrelli, E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05848.2000 · Cited by 180
Lundblad, M., Vaudano, E., & Cenci, M. A. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01632.x · Cited by 168
Rosin, D. L., Hettinger, B. D., Lee, A., & Linden, J. (2003) · Neurology · doi:10.1212/01.wnl.0000095205.33940.99 · Cited by 162
Istradefylline, a novel adenosine A2Areceptor antagonist, for the treatment of Parkinson’s disease
Jenner, P. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.729 · Cited by 160
Mori, A., & Shindou, T. (2003) · Neurology · doi:10.1212/01.wnl.0000095211.71092.a0 · Cited by 122
Self-citationIndustry forum: Progress in pursuit of therapeutic A2Aantagonists
Kase, H., Aoyama, S., Ichimura, M., Ikeda, K., Ishii, A., Kanda, T., Koga, K., Koike, N., Kurokawa, M., Kuwana, Y., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000095219.22086.31 · Cited by 111
Self-citationAdenosine A2A receptors modify motor function in MPTP-treated common marmosets
Kanda, T., Tashiro, T., Kuwana, Y., & Jenner, P. G. (1998) · Neuroreport · doi:10.1097/00001756-199808240-00032 · Cited by 102
Pathophysiology of motor fluctuations in Parkinson's disease
Widnell, K. L. (2005) · Movement Disorders · doi:10.1002/mds.20459 · Cited by 66
The effect of the adenosine A2A antagonist KW-6002 on motor and motivational processes in the rat
O’Neill, M. J., & Brown, V. J. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0240-z · Cited by 30
Cited by
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Linden, J., & Müller, C. E. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003285 · Cited by 1,301
Epidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199
Fox, S. H., Katzenschlager, R., Lim, S., Barton, B., de Bie, R. M. A., Seppi, K., Coelho, M., Sampaio, C., & on behalf of the Movement Disorder Society Evidence‐Based Medicine Committee (2018) · Movement Disorders · doi:10.1002/mds.27372 · Cited by 1,002
Adenosine receptors as drug targets — what are the challenges?
Chen, J.-F., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 895
Extracellular adenosine triphosphate and adenosine in cancer
Stagg, J., & Smyth, M. J. (2010) · Oncogene · doi:10.1038/onc.2010.292 · Cited by 571
Metadata
- Authors
- LeWitt, P. A., Guttman, M., Tetrud, J. W., Tuite, P. J., Mori, A., Chaikin, P., Sussman, N. M., & 6002‐US‐005 Study Group
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2008-03
- Volume
- 63
- Issue
- 3
- Pages
- 295-302
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2088277236
- Cited by
- 356
- References
- 23
- FWCI
- 18.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.